Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. - Wikidata - awgldk - TriplyDB

Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.

Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.

http://www.wikidata.org/entity/Q44064682

about

Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function Histoplasmosis: a clinical and laboratory update continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Antifungal clinical trials and guidelines: what we know and do not know Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy eras Incidence, Predictors, and Impact on Hospital Mortality of Amphotericin B Nephrotoxicity Defined Using Newer Acute Kidney Injury Diagnostic Criteria Therapy of systemic fungal infections.Combination therapy for mucormycosis: why, what, and how?Gastrointestinal histoplasmosis.Liposomal amphotericin B: clinical experience and perspectives.Histoplasmosis: a review for clinicians from non-endemic areas.Improvements in diagnosis of histoplasmosis.An update on the use of antifungal agents.Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Fungal infections in intensive care unit: challenges in diagnosis and management Current options in antifungal pharmacotherapy.Antifungal therapies in the intensive care unit.Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized Treatment of endemic mycoses.Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.Amphotericin B use in children: conventional and lipid-based formulations.Management of fungal lung disease in the immunocompromised.Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.Eradication of superficial fungal infections by conventional and novel approaches: a comprehensive review.Progressive disseminated histoplasmosis in the HIV population in Europe in the HAART era. Case report and literature review.Comparison between liposomal formulations of amphotericin B.Synthesis and antifungal activity in vitro of isoniazid derivatives against histoplasma capsulatum var. capsulatum.AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy.Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis.Histoplasmosis in transplant recipients.Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies.Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens.Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center.[Disseminated histoplasmosis in Rio Grande do Sul].

P2860

Q24187699-84154F96-DCCE-45E6-B9FB-D8B5242DAA63 Q24675642-1915D11B-6E71-45E5-9249-76EB7C6E05DB Q28534551-15ED3EB1-BD26-45E5-B675-4BCF16E2D2C8 Q30240770-E4B9FDFD-D4E2-46DC-BEAB-675F1B441234 Q33753500-FD830295-794C-4216-A7A2-D418CDB3D078 Q34212799-FCE73F09-FC6D-4310-8995-CF035FB6A8A4 Q34400255-C0993797-CB4E-4464-9C30-3C7646B284E5 Q34960317-87BE0BBA-01EE-4FAE-AC69-F851C9164D1C Q35494596-465916A4-3C24-4C92-9535-29477DBF0EAF Q35860053-3E55A10B-05B4-45AB-A79E-09DC5B9BC389 Q35967453-84A1FB9F-F663-41BB-A4C8-0B47028F8D8C Q35974333-084C36A5-1FDB-4FA5-92E2-23F42C2B8288 Q36011779-DD317FAD-E148-40F1-A201-CB2AFEF8DE0B Q36140647-FFAEC220-F557-43A3-9D34-F953873E51C4 Q36511359-8883401B-F104-4688-82B9-0E99C66BFA85 Q36627264-CCAF97F2-8892-4C1A-B9E9-061D1D8629D1 Q36724783-7A0F0429-E65F-4763-80E2-11014D938B51 Q36868273-4D7FA3EF-894E-43C2-863B-645C6C467B92 Q37058527-2572ECBA-152C-4AEA-A080-8F0842070442 Q37151326-41F2FB34-6DE5-4271-8005-CFF17DCD674C Q37161793-F20372B5-1CEF-4158-A640-092AB1A16673 Q37164085-8C53804C-1A12-4B19-9DD5-F29F9FF602A7 Q37393668-B489031F-54BB-49A9-AC08-7B669E44322C Q37729998-6217EFAD-5B43-43E8-909F-14C606973897 Q37816399-99631030-E08B-4A2B-9986-E27733F72CA0 Q37854727-7028C66E-07DE-4C17-90C5-6024FAD4A569 Q37909774-ABE4C01D-B1D6-4D50-A813-1E86E234180A Q38077678-32C3F62C-383E-4EC0-A892-EEAEC541F735 Q38079194-3AB734CB-C623-4A3C-A6DD-11C6B93BCBE9 Q38085729-3B1968D8-C312-4FC6-A599-46C1A2BB88C7 Q38195802-483E24F5-1F8F-420F-AA3B-1F196E06934C Q38696930-9F17796B-87DF-4573-B1F3-279BE7AF5A56 Q38848844-8F9AEB86-E306-40C1-9BC0-7930FA0AFAB5 Q38872275-ABF752C0-CDA4-4A96-84DF-531FC00377D2 Q40043040-FC1CCA4A-8F54-49B5-ADB3-A11C662D0EFB Q40043530-6D3D57A6-7ADE-44B8-8162-AA8226BC623E Q40175242-3D8A4A7A-9ABC-4AFF-BB6E-B1ADE8524466 Q40222438-DE48DFBD-20E1-442B-85A0-11AFD29BF117 Q40489588-6A514FDE-4748-43C3-B23E-CEEAAEB5C927 Q40513117-4439CD19-9245-4E79-9CBA-D0B87EE913AE

P2860

Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.

http://www.wikidata.org/entity/Q44064682

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Safety and efficacy of liposom ...... asmosis in patients with AIDS.

@en

Safety and efficacy of liposom ...... asmosis in patients with AIDS.

@nl

type

label

Safety and efficacy of liposom ...... asmosis in patients with AIDS.

@en

Safety and efficacy of liposom ...... asmosis in patients with AIDS.

@nl

prefLabel

Safety and efficacy of liposom ...... asmosis in patients with AIDS.

@en

Safety and efficacy of liposom ...... asmosis in patients with AIDS.

@nl

P1433

Q44064682-C2374F74-8AFA-4671-90DE-35CB6C8AE0EE

P1476

Q44064682-BF2AA957-0E8F-4B09-88AA-6A4EF975A810

P2093

Q44064682-2D5350AD-A8A8-41C1-8796-6CFD3B6AC58C

Q44064682-554D9A42-693F-44F2-ACB3-16A377DA5C52

Q44064682-8594F49A-D151-429E-AF05-68A2769BBBEC

Q44064682-8A339F79-AEED-4D32-A259-534D54CD5185

Q44064682-A62D18DA-1344-43A8-AE7D-FD7E67F4A554

Q44064682-A77171CA-A132-45AD-8CFC-EBAD8BAE180C

Q44064682-B4197DCD-5A98-43A1-B697-2409A9FE017F

Q44064682-CE1A8E55-0971-41BA-A68D-0414A457DA9A

Q44064682-F40EA508-7678-422B-89DE-CB5F46229042

Q44064682-FCB9B77A-2A59-4F2F-BDC6-493F6F1D2415

P304

Q44064682-6855A0C5-2E8E-45FE-802D-4B55DB4775BD

P31

Q44064682-A55EA100-EF6F-4572-9A97-B964AB91DA2E

P356

Q44064682-3541BDB8-DC1F-4344-8AB6-08F6B713D658

P407

Q44064682-88AEF2E9-5D2C-4F88-B49D-2ADA5DC02440

P433

Q44064682-8AE03997-86A9-4BBF-BFCF-E23E480492E6

P478

Q44064682-46CE6C51-A269-4692-B302-11005069B988

P50

Q44064682-DB5FC59E-C729-48A6-A13F-605195E25238

P577

Q44064682-4C4496A8-D2CA-41F2-9A11-7C521218DA1B

P698

Q44064682-88D37C4E-38CA-4075-878C-CCC8823FB939

P921

Q44064682-06DD432F-73AB-4964-ADF1-B2C3455332B5

Q44064682-B2787952-5D25-4AE6-B7BF-2541DB082ED7

P356

0003-4819-137-2-200207160-00008

P1433

Annals of Internal Medicine

P1476

Safety and efficacy of liposom ...... asmosis in patients with AIDS.

@en

P2093

Carol A Kauffman

http://www.w3.org/2001/XMLSchema#string

Dan Lancaster

http://www.w3.org/2001/XMLSchema#string

David M Bamberger

http://www.w3.org/2001/XMLSchema#string

Gretchen A Cloud

http://www.w3.org/2001/XMLSchema#string

Mitchell Goldman

http://www.w3.org/2001/XMLSchema#string

Philip C Johnson

http://www.w3.org/2001/XMLSchema#string

Richard Hafner

http://www.w3.org/2001/XMLSchema#string

U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group

http://www.w3.org/2001/XMLSchema#string

William E Dismukes

http://www.w3.org/2001/XMLSchema#string

William G Powderly

http://www.w3.org/2001/XMLSchema#string

P304

105-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-137-2-200207160-00008

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12118965

http://www.w3.org/2001/XMLSchema#string

P921